Mode
Text Size
Log in / Sign up
Phase 4 N=350 Randomized Treatment

A Trial of Oral Misoprostol for Labor Augmentation

Labor Augmentation

Enrolled (actual)
350
Serious AEs
0.9%
Results posted
Nov 2012
Primary outcome: Primary: Uterine Tachysystole — 50; 41 participants

Study Design & Population

Study type
Interventional
Phase
Phase 4
Interventions
Misoprostol (Drug); Oxytocin (Drug)
Age
Pediatric, Adult, Older Adult · 16+ yrs
Sex
Female
Sponsor
University of Texas Southwestern Medical Center
Primary completion
Jan 2011

Outcome Measures

OutcomeResultp-value
PRIMARY
Uterine Tachysystole
50; 41
SECONDARY
Infant Apgar Score <4
0; 0
SECONDARY
Umbilical Cord Artery pH <7.1
3; 4
SECONDARY
Admission of Neonatal Intensive Care Unit
1; 0
SECONDARY
Maternal Chorioamnionitis
28; 32
SECONDARY
Maternal Hypovolemia Requiring Blood Transfusion
6; 2
SECONDARY
Method of Delivery
153; 154; 4; 2; 11; 13
SECONDARY
Time Elapsed From Start of Labor Augmentation to Delivery
306; 276

Summary

This is a prospective, randomized, controlled trial designed to examine the efficacy of oral misoprostol for labor augmentation compared to a standard regimen of intravenous oxytocin.

Eligibility Criteria

Inclusion Criteria

  • Clinical decision to augment labor
  • Gestational age > than or equal to 36 weeks
  • Singleton gestation
  • Cephalic presentation
  • Reassuring fetal heart rate tracing
  • Cervical dilation between 4 and 8 cm
  • Ruptured membranes with clear amniotic fluid
  • Intrauterine pressure catheter in place
  • Less than 200 MVUs in a 10 minute period
  • 5 or fewer contractions in a 10 minute period
  • English or Spanish speaking patient

Exclusion Criteria

  • Non-reassuring fetal heart rate tracing at time of enrollment
  • Meconium stained amniotic fluid
  • Previous uterine incision
  • Maternal fever (defined as greater than 37.9 C)
  • Known fetal anomalies
  • Placenta previa or unexplained vaginal bleeding
  • Estimated fetal weight of 4, 500 grams or more
  • Abnormal maternal bony pelvis
  • Grandmultiparity
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00906347). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search